MEDROGESTONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H32O2
Molecular Weight	340.499
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C=C(C)C4=CC(=O)CC[C@]34C

InChI

InChIKey=HCFSGRMEEXUOSS-JXEXPEPMSA-N

InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H32O2
Molecular Weight	340.499
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4288903
Curator's Comment: description was created based on several sources, including http://www.cngof.asso.fr/d_livres/1996_GO_157_laurent.pdf

Medrogestone is a progesterone derivative used for the treatment of progesterone deficiency, especially those observed in the premenopausal period, haemorrhages and menorrhagia of fibroids, endometriosis, menstrual cycle disorders, etc. The drug acts by binding and activating progesterone receptors. In Europe, medrogestone is available under the name Colprone, however it is no longer marketed in the USA, Germany and Austria.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Progesterone receptor 61 Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4288903	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Progesterone deficiency 1 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Primary	Approved 8429	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Dysmenorrhea 9 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Primary	Approved 8429	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Endometriosis 32 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Palliative	Approved 8429	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Menstrual cycle disorder 5 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Primary	Approved 8429	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Functional haemorrhages and menorrhagia of fibroids 1 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Primary	Approved 8429	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.

PubMed

Title	Date	PubMed
Biological effects of progestins in breast cancer.	2001 Dec	12227886
Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone.	2002 Dec 10	12468135
Influence of different HRT regimens on mammographic density.	2005 Feb 14	15653007
Breast cancer risk associated with different HRT formulations: a register-based case-control study.	2006 Sep 12	16965641
Estrogen sulfotransferases in breast and endometrial cancers.	2009 Feb	19250196

Patents

Sample Use Guides

In Vivo Use Guide

Take two tablets (10 mg) per day.

Route of Administration: Oral

In Vitro Use Guide

T-47D cells were incubated with medrogestone for 24h and the drug inhibited 17beta-hydroxysteroid dehydrogenase activity in a dose-dependent manner by 39% and 80% at 5 x 10(-8) M and 5 x 10(-5) M.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:24:51 UTC 2023` Edited by `admin` on `Sat Dec 16 17:24:51 UTC 2023`
Record UNII	077DN93G5B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEDROGESTONE

Official Name

English

MEDROGESTONE [USAN]

Common Name

English

NSC-123018

Code

English

MEDROGESTONE [MI]

Common Name

English

AY-13615

Code

English

COLPRO

Brand Name

English

PREGNA-4,6-DIENE-3,20-DIONE, 6,17-DIMETHYL-

Systematic Name

English

AY-62022

Code

English

METROGESTONE

Common Name

English

AY 62022

Code

English

PROTHIL

Brand Name

English

AY-13615S

Code

English

MEDROGESTERONE

Common Name

English

medrogestone [INN]

Common Name

English

6,17-Dimethylpregna-4,6-diene-3,20-dione

Systematic Name

English

Medrogestone [WHO-DD]

Common Name

English

COLPRONE

Brand Name

English

ETOGYN

Brand Name

English

MEDROGESTONE [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ATC

G03DB03